Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women

Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women

Chemotherapy and endocrine therapies are mainstays of treatment for early and advanced hormone receptor-positive (HR+) breast cancer. In premenopausal women with HR+ tumors, the benefits of adding ovarian function suppression (OFS) to endocrine therapy have been debated. Consequently, for many years...

Full description

Bibliographic Details
Main Authors: Yen-Shen Lu, Andrea Wong, Hee-Jeong Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
premenopausal
breast cancer
ovarian function suppression (OFS)
ovarian function preservation
endocrine therapy
luteinizing hormone releasing hormone
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.700722/full

Similar Items

Similar Items